Overview

A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors

Status:
Not yet recruiting
Trial end date:
2026-05-31
Target enrollment:
Participant gender:
Summary
This study is a prospective, multi-cohort, single-centre, phase II clinical trial designed to initially explore the efficacy and safety of sequential fluzoparib with chemoradiotherapy in pan-solid tumours. The study is designed for patients with untreated surgically resectable rectal cancer and untreated locally advanced unresectable non-small cell lung cancer, oesophageal squamous cancer, and cervical cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Chongqing University Cancer Hospital
Treatments:
Capecitabine
Fluzoparib